Enzene Biosciences has opened its first fully connected continuous biologics manufacturing facility in Pune, India. This first-of-its-kind facility has a significantly smaller footprint than the conventional manufacturing facilities and Enzene is among the first to set up a fully automated continuous cGMP compliant manufacturing plant for mAb production.

According to the company, this plant is capable of delivering higher production and will enable Enzene to move early/preclinical assets to late stage development or to the commercial stage faster, compared to a traditional manufacturing plant.

“Some of the world’s biggest drugs are biologics and Alkem laboratories Ltd. always aspired to enter the arena of biologics. With that intent, we have invested significantly into this space. Our new biologics manufacturing plant endorses our commitment to expand into the space of biotech innovations,” said Mr. Sandeep Singh of Alkem Laboratories Ltd.

Enzene aims to broaden its footprint for innovative technologies through strategic global alliances and has taken first steps by procuring its first European client project for cGMP manufacturing of clinical material.  

“High cost of manufacturing is one of the major barriers for the entry of biologics into the clinical stage of development. Enzene wishes to disrupt this cost barrier through the launch of their innovative manufacturing plant,” said Dr. Himanshu Gadgil, director and chief scientific officer at Enzene.